Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma
Status:
Active, not recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
The goal of this type of study: clinical trial is to observe the efficacy and safety of
cardunilizumab in soft tissue sarcomas after failure of at least first-line
anthracycline-based chemotherapeutic agents, including undifferentiated sarcoma (UPS), smooth
muscle sarcoma, mucinous fibrosarcoma, and poorly differentiated/undifferentiated/polymorphic
liposarcoma, etc.) . The main question[s] it aims to answer are:
- Cardunilizumab is effective in soft tissue sarcomas after failure of at least first-line
anthracycline-based chemotherapeutic agents, including undifferentiated sarcoma
(UPS),smooth muscle sarcoma, mucinous fibrosarcoma, and poorly
differentiated/undifferentiated/polymorphic liposarcoma) is effective .
- Cardunilizumab has manageable adverse effects. Participants will be given Cardunolizumab
6mg/kg once every 2 weeks free